Treatment of Vasovagal Syncope

Introduction to Treatment

The European Society of Cardiology recommends patient education and reassurance about the benign prognosis as mandatory for all patients, followed by physical counterpressure maneuvers and increased salt/fluid intake, with midodrine as the only evidence-based first-line pharmacological option if non-pharmacological measures fail 1, 2

Treatment is not necessary for patients with a single syncope episode who are not in high-risk settings, according to the European Heart Journal 3, 1, 2
The European Heart Journal suggests that treatment becomes essential when syncope is recurrent and unpredictable with absent or minimal prodromal symptoms 3
The European Heart Journal also recommends treatment for patients who work in high-risk occupations, such as commercial drivers, pilots, machine operators, and competitive athletes 4, 3, 1

The European Society of Cardiology recommends that all patients receive education explaining that vasovagal syncope is not life-threatening and has an excellent prognosis, including recognition of prodromal symptoms and trigger avoidance 4, 3, 1, 2

The European Heart Journal suggests that physical counterpressure maneuvers, such as leg crossing with muscle tensing, squatting, and isometric arm contraction or handgrip, should be taught to all patients with adequate prodromal warning 4, 3, 1, 2

The European Heart Journal recommends increased dietary salt and fluid intake as the safest initial approach, unless contraindicated by hypertension, heart failure, or renal disease 4, 1, 2
The European Heart Journal also suggests additional options, such as salt tablets or sport drinks, head-up tilt sleeping, compression garments or abdominal binders, moderate exercise training, and tilt-training 4, 1, 2

The European Society of Cardiology recommends midodrine as the only pharmacologic agent with consistent evidence of efficacy and should be the first-line drug for recurrent vasovagal syncope, reducing syncope recurrence by 43% in meta-analysis of 5 randomized controlled trials 2
The European Heart Journal suggests considering fludrocortisone only in patients who don't respond to non-pharmacological measures and midodrine, particularly useful in young patients with orthostatic form and low-normal blood pressure 4, 1, 2
The European Heart Journal recommends against the use of beta-blockers as first-line therapy, as evidence fails to support efficacy and may aggravate bradycardia in cardioinhibitory cases 4, 3, 1, 2

The European Heart Journal suggests that dual-chamber pacing might be reasonable only in highly selected patients meeting specific criteria, including age >40 years, documented cardioinhibitory response, frequency >5 attacks per year with severe physical injury, and all other therapies have failed 4, 3, 2